{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:16:09Z","timestamp":1793304969976,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The current study was performed to evaluate risk factors for severe coronavirus disease 2019 (COVID-19) outcomes among Medicare beneficiaries during the pandemic\u2019s early phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective cohort study covering Medicare fee-for-service beneficiaries, we separated out elderly residents in nursing homes (NHs) and those with end-stage renal disease (ESRD) from the primary study population of individuals age \u226565 years. Outcomes included COVID-19 hospital encounters and COVID-19-associated deaths. We estimated adjusted odds ratios (ORs) using logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed 25 333 329 elderly non-NH beneficiaries without ESRD, 653 966 elderly NH residents, and 292 302 patients with ESRD. COVID-related death rates (per 10 000) were much higher among elderly NH residents (275.7) and patients with ESRD (60.8) than in the primary study population (5.0). Regression-adjusted clinical predictors of death among the primary population included immunocompromised status (OR, 1.43), frailty index conditions such as cognitive impairment (3.16), and other comorbid conditions, including congestive heart failure (1.30). Demographic-related risk factors included male sex (OR, 1.77), older age (3.09 for 80- vs 65-year-olds), Medicaid dual-eligibility status (2.17), and racial\/ethnic minority. Compared with whites, ORs were higher for blacks (2.47), Hispanics (3.11), and Native Americans (5.82). Results for COVID-19 hospital encounters were consistent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Frailty, comorbid conditions, and race\/ethnicity were strong risk factors for COVID-19 hospitalization and death among the US elderly.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiaa767","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T20:20:37Z","timestamp":1607977237000},"page":"945-956","source":"Crossref","is-referenced-by-count":62,"title":["Natural History of Coronavirus Disease 2019: Risk Factors for Hospitalizations and Deaths Among &amp;gt;26 Million US Medicare Beneficiaries"],"prefix":"10.1093","volume":"223","author":[{"given":"Hector S","family":"Izurieta","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Graham","sequence":"additional","affiliation":[{"name":"Center for Drugs Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Jiao","sequence":"additional","affiliation":[{"name":"Acumen, LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hu","sequence":"additional","affiliation":[{"name":"Acumen, LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Acumen, LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[{"name":"Acumen, LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[{"name":"Acumen, LLC, Burlingame, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Menis","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Pratt","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kelman","sequence":"additional","affiliation":[{"name":"Centers for Medicare $ Medicaid Services, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Forshee","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2021032911261706700_CIT0001","author":"Center for Systems Science and Engineering at Johns Hopkins University."},{"key":"2021032911261706700_CIT0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.15585\/mmwr.mm6908e1","article-title":"Update: public health response to the coronavirus disease 2019 outbreak\u2014United States, February 24, 2020","volume":"69","author":"Jernigan","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0003","doi-asserted-by":"crossref","first-page":"759","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus disease 2019 case surveillance\u2014United States, January 22-May 30, 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15585\/mmwr.mm6905e1","article-title":"Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak\u2014United States, December 31, 2019-February 4, 2020","volume":"69","author":"Patel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.15585\/mmwr.mm6918e1","article-title":"Characteristics and clinical outcomes of adult patients hospitalized with COVID-19\u2014Georgia, March 2020","volume":"69","author":"Gold","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0007","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.2020.7202","article-title":"Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California","volume":"323","author":"Myers","year":"2020","journal-title":"JAMA"},{"key":"2021032911261706700_CIT0008","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2021032911261706700_CIT0009","doi-asserted-by":"crossref","first-page":"382","DOI":"10.15585\/mmwr.mm6913e2","article-title":"Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019\u2014United States, February 12-March 28, 2020","volume":"69","author":"COVID-19 Response Team","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","article-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19)\u2014United States, February 12-March 16, 2020","volume":"69","author":"COVID-19 Response Team","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0011","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.3346\/jkms.2020.35.e237","article-title":"Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study","volume":"35","author":"Ji","year":"2020","journal-title":"J Korean Med Sci"},{"key":"2021032911261706700_CIT0012","first-page":"17","article-title":"Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a systemic review and meta-analysis","volume":"2020","author":"Wang","year":"2020","journal-title":"J Research"},{"key":"2021032911261706700_CIT0013","author":"University of Wisconsin School of Medicine and Public Health"},{"key":"2021032911261706700_CIT0014","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/aje\/kwx257","article-title":"External validation of the claims-based frailty index in the national health and aging trends study cohort","volume":"186","author":"Segal","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2021032911261706700_CIT0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty indicator anchored to a well-established frailty phenotype","volume":"55","author":"Segal","year":"2017","journal-title":"Med Care"},{"key":"2021032911261706700_CIT0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1513\/AnnalsATS.201507-415BC","article-title":"Validation of a method to identify immunocompromised patients with severe sepsis in administrative databases","volume":"13","author":"Greenberg","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2021032911261706700_CIT0017","first-page":"27","article-title":"More accurate racial and ethnic codes for Medicare administrative data","volume":"29","author":"Eicheldinger","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"2021032911261706700_CIT0018","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MLR.0000000000001216","article-title":"Validity of race and ethnicity codes in Medicare administrative data compared with gold-standard self-reported race collected during routine home health care visits","volume":"58","author":"Jarr\u00edn","year":"2020","journal-title":"Med Care"},{"key":"2021032911261706700_CIT0019","author":"Centers for Disease Control and Prevention"},{"key":"2021032911261706700_CIT0020","article-title":"Assessment of COVID-19 hospitalizations by race\/ethnicity in 12 states","author":"Karaca-Mandic","journal-title":"JAMA Intern Med"},{"key":"2021032911261706700_CIT0021","doi-asserted-by":"crossref","first-page":"923","DOI":"10.15585\/mmwr.mm6928e1","article-title":"Characteristics of persons who died with COVID-19\u2014United States, February 12-May 18, 2020","volume":"69","author":"Wortham","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021032911261706700_CIT0022","first-page":"9","article-title":"Medical insurance claims as a source of data for research: accuracy of diagnostic coding","volume":"55","author":"Worth","year":"1996","journal-title":"Hawaii Med J"},{"key":"2021032911261706700_CIT0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ajh.10445","article-title":"Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study","volume":"75","author":"Segal","year":"2004","journal-title":"Am J Hematol"},{"key":"2021032911261706700_CIT0024","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.vaccine.2019.08.045","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after 2015\u20132016 and 2016\u20132017 influenza vaccination of Medicare beneficiaries","volume":"37","author":"Arya","year":"2019","journal-title":"Vaccine"},{"key":"2021032911261706700_CIT0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/infdis\/jiy716","article-title":"Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017\u201318","volume":"220","author":"Izurieta","year":"2019","journal-title":"J Infect Dis"},{"key":"2021032911261706700_CIT0026","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/infdis\/jiaa080","article-title":"Relative effectiveness of influenza vaccines among the United States elderly, 2018\u20132019","volume":"222","author":"Izurieta","year":"2020","journal-title":"J Infect Dis"},{"key":"2021032911261706700_CIT0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021032911261706700_CIT0028","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021032911261706700_CIT0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/pds.4801","article-title":"Zostavax vaccine effectiveness among US elderly using real-world evidence: addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claims","volume":"28","author":"Izurieta","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021032911261706700_CIT0030","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/infdis\/jiz360","article-title":"Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries aged \u226565 years","volume":"220","author":"Lu","year":"2019","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa767\/36157664\/jiaa767.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/6\/945\/36785452\/jiaa767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/6\/945\/36785452\/jiaa767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T22:42:57Z","timestamp":1670193777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/6\/945\/6039057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,3,29]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa767","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,15]]},"published":{"date-parts":[[2020,12,16]]}}}